You are here

  • Home
  • Archive
  • Volume 15, Issue Suppl 2
  • 000103 PACLITAXEL-CARBOPLATIN-GEMCITABINE VS. PACLITAXEL-CARBOPLATIN AS FIRSTLINE TREATMENT OF OVARIAN CANCER: A RANDOMIZED PHASE III GCIG INTERGROUP STUDY (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102)

Citation Tools

Article menu
Download PDFPDF
Oral Presentations – Thursday, September 29, 2005
000103 PACLITAXEL-CARBOPLATIN-GEMCITABINE VS. PACLITAXEL-CARBOPLATIN AS FIRSTLINE TREATMENT OF OVARIAN CANCER: A RANDOMIZED PHASE III GCIG INTERGROUP STUDY (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
du Bois A, Schroeder W, Jelic S, et al
000103 PACLITAXEL-CARBOPLATIN-GEMCITABINE VS. PACLITAXEL-CARBOPLATIN AS FIRSTLINE TREATMENT OF OVARIAN CANCER: A RANDOMIZED PHASE III GCIG INTERGROUP STUDY (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102)
International Journal of Gynecologic Cancer 2005;15:80.